Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.

摘要: Objectives We sought to determine whether the addition of spironolactone angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventricular mass arterial stiffness in early-stage chronic kidney disease (CKD). Background Chronic is associated with a high risk cardiovascular prevalence hypertrophy that confer an adverse prognosis. It believed these abnormalities are part result activation renin-angiotensin-aldosterone system. Methods After active run-in phase 25 mg once daily, 112 patients stage 2 3 CKD good blood pressure control (mean daytime ambulatory Results Compared placebo, use resulted significant improvements (−14 ± 13 g vs. +3 11 g, p Conclusions The reduces CKD. These effects suggest aldosterone exerts worthy further study as treatment could reduce events. (Is Spironolactone Safe Effective Treatment Cardiovascular Disease Mild Renal Failure; NCT00291720)